Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00401362 · ClinicalTrials.gov registry record · Phase 3
A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients
A Phase 3 study of Advanced Illness Patients With Opioid Induced Constipation, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 154
- Enrollment target
- 1
- Study location
NCT00401362 is a Phase 3 study of Advanced Illness Patients With Opioid Induced Constipation that has completed, run by Bausch Health Americas. The registered enrollment target is 154 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00401362, a Phase 3 study of Advanced Illness Patients With Opioid Induced Constipation, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 154 participants
- Enrollment target
- 1
- Study location
Study Summary
To test the effectiveness of MNTX in advanced illness subjects.
Conditions Studied
Interventions
- DRUG SC Placebo
- DRUG SC Methylnaltrexone
Study Locations (1)
New York
- Progenics Pharmaceuticals, Inc. - Tarrytown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2003-02 |
| Est. Completion | 2005-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00401362
The ClinicalTrials.gov registry entry for NCT00401362 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Illness Patients With Opioid Induced Constipation appearing as the primary indexed condition, and to 2 interventions - of which SC Placebo is the first listed.
NCT00401362 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00401362 about?
NCT00401362 is a clinical study titled "A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients". To test the effectiveness of MNTX in advanced illness subjects.
What is the current status of trial NCT00401362?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 154 participants. The study started on 2003-02. Estimated completion is 2005-02.
What conditions does trial NCT00401362 study?
This clinical trial studies the following conditions: Advanced Illness Patients With Opioid Induced Constipation.
What interventions are being tested in trial NCT00401362?
The interventions under investigation include: SC Placebo (DRUG), SC Methylnaltrexone (DRUG).
Who is sponsoring clinical trial NCT00401362?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00401362 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.